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Abstract
As cancer advances, cells often spread from the primary tumor to other parts of the body and form
metastases. This is the main cause of cancer related mortality. Here we investigate a conceptually simple
model of metastasis formation where metastatic lesions are initiated at a rate which depends on the
size of the primary tumor. The evolution of each metastasis is described as an independent branching
process. We assume that the primary tumor is resected at a given size and study the earliest time at
which any metastasis reaches a minimal detectable size. The parameters of our model are estimated
independently for breast, colorectal, headneck, lung and prostate cancers. We use these estimates to
compare predictions from our model with values reported in clinical literature. For some cancer types,
we find a remarkably wide range of resection sizes such that metastases are very likely to be present, but
none of them are detectable. Our model predicts that only very early resections can prevent recurrence,
and that small delays in the time of surgery can significantly increase the recurrence probability.
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1 Introduction
Metastases develop as cancer cells disseminate from a primary tumor and establish new malignant lesions in
the surrounding tissue or at other sites [1]. However, the full process of metastasis formation is much more
complex and many related aspects are not yet fully understood. In particular, it is still unclear whether
metastases are initiated during early or late stages of carcinogenesis (see e.g. [2, 3, 4]). These details,
however, affect the chances of a patient presenting detectable or undetectable metastases at diagnosis,
which in turn influence treatment strategies and prognosis. For these reasons, different authors (see e.g.
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[5, 6] and the references therein) have proposed mathematical models to improve our understanding of the
dynamics of metastasis formation.
Metastases frequently arise in cancer patients, and their occurrence greatly diminishes the chances of
effective treatment. In fact, even when a therapy is initially successful, metastases often lead to relapse and
are responsible for an estimated 90% of cancer related deaths [7]. Despite this common disease progression,
reliable predictions for cancer recurrence rates and times are still lacking [8].
Recently, many generalizations of the Luria-Delbru¨ck model [9] have been employed to study specific
traits of tumor evolution, such as the development of drug resistance [10, 11, 12, 13], the role of driver
mutations [14, 15] and metastasis formation [5, 6, 16, 17]. Another line of research focused on temporal
features, after the first stochastic model for the time to tumor onset was proposed by Armitage and Doll
in their pioneering work on carcinogenesis [18]. A few decades later authors began to investigate stochastic
models of tumor latency time. In particular, these works led to mathematical descriptions of optimal
schedules of cancer surveillance [19, 20], cure rates [21] and cancer recurrence [22]. These models are
studied in the context of survival analysis and reviewed in the excellent book of Yakovlev and Tsodikov
[23].
In this paper we build a model for cancer recurrence by joining these two approaches, that is we use
Luria-Delbru¨ck type models to study cancer relapse times. In particular, we consider a deterministically
growing tumor seeding metastases at a rate depending on its size [24], and model the evolution of each
metastasis (or clone) as independent birth-death branching processes. A similar setup was used by Lea
and Coulson to mimic mutations occurring in a growing bacterial population [25]. In our model though
we interpret these mutation events (from wild-type cells to mutants) as metastasis initiation events. The
distribution of mutant close sizes was studied with an exponentially growing wild-type population [26] and
with more general wild-type growth function [16]. Kendall [27] also allowed the wild-type population to
grow stochastically, but this extension left the mutant behavior unchanged for small initiation (mutation)
rates [28, 29]. Hence in this paper we model the size of the primary tumor as a deterministic function
(focusing on exponential and logistic growth as examples), while allow the seeded metastases to evolve
stochastically according to branching processes.
Within this framework we study the time to cancer relapse, defined as the interval between the primary
onset and the first time that any of the metastases reaches a fixed detectable size. Similar characterizations
are employed in the threshold models described in [23, 22].
The rest of the paper is organized as follows: In Results we present our mathematical model of metas-
tases initiation and growth, and derive an explicit formula for the probability distribution of the time to
relapse. We then extend our model to include the resection of the primary tumor at a given time and
distinguish between synchronous and metachronous metastases. In Discussion we report parameter esti-
mates for five different cancer types (namely breast, colorectal, headneck, lung and prostate) and analyze
the corresponding predictions yielded by our model. Quantitative results are compared with data collected
from clinical literature. In Material and Methods we present details about the mathematical formulation
of our model and related derivations.
2 Results
Our mathematical characterization of the time to cancer recurrence is based on a stochastic model of
metastasis formation. We first present the fundamental assumptions and features of this model, and then
use them to derive the probability distribution of the time to relapse.
2.1 Model setup
We model the number of cells in the primary tumor as a deterministic function of time n(t). The tumor
initiates metastases at rate νn(t), where ν is constant. We implicitly assume that all tumor cells can
metastasize at the same rate. Since we make no assumptions on n(t), one can define initiation at rate
νn(t)γ to model scenarios where only a fraction of the primary tumor can metastasize, for example only
the cells near its surface or close to blood vessels (see e.g. [6]). The initiated metastases are then modelled
as independent branching birth-death processes [31], all with the same birth rate α and death rate β.
We assume that they are supercritical, that is they have a positive net growth rate λ = α − β > 0, and
consequently grow exponentially for large times [31]. Exponential growth has also been observed in clinical
studies [32] for untreated human lung metastases, which supports our modelling choice.
Under these assumptions each metastasis will eventually go extinct with probability q = β/α < 1. The
surviving ones instead grow unboundedly and will reach any given size [31]. Let M be a fixed number of
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Figure 1: Sample realisation of the model obtained by simulations. The primary tumor grows according to a deter-
ministic exponential function n(t) - depicted by the blue line. It initiates distant metastases at rate νn(t), and each
of them grows as an independent branching process (only the first five are plotted). The first time τ that any of these
metastases reaches a minimal detectable size M is defined as the time to cancer relapse. Also, the primary tumor
is surgically removed at a given time T , when it is made of N = n(T ) cells. In the realisation shown, the third
established metastases (green curve) is the first to reach detectable size, and hence determines the time to cancer
relapse τ . Based on clinical data (summarized in Table 1), we estimated model parameters (summarized in Table 2),
and here we use those for colorectal cancer, with N = 2 × 1011. Note that a similar illustration for metastasis
formation appears in [30].
cells representing the minimal detectable size of a cancerous lesion. We aim to describe the time to cancer
recurrence, defined as the first time τ that any metastasis reaches the detectable size M .
The minimal detectable sizeM is typically very large, with estimates over 106 (see parameter estimations
in Discussion). As the probability that a large supercritical population goes extinct is negligibly small, we
assume that each metastasis survives indefinitely if it reaches M . Then, due to the splitting property of
Poisson processes, the surviving metastases that eventually reach the detectable size are initiated as a non-
homogeneous Poisson process (Kt)t≥0 with rate ν(1 − q)n(t). Here Kt denotes the number of metastases
established by t, conditioned on survival. The expected number of established metastases at time t is thus
at = E[Kt] = ν(1 − q)
∫ t
0
n(s)ds
and the probability that at least one is present at t is equal to
P(Kt ≥ 1) = 1− e
−at (1)
Surviving metastases are initiated at times σi := inf{t ≥ 0 : Kt = i} and are described by i.i.d. birth-
death processes (Si(s))s≥0, where Si(s) is the number of cells in the i-th metastasis at time s after its
establishment. In particular, we have Si(0) = 1 for every i. For each of these processes we define Θi :=
inf{s ≥ 0 : Si(s) = M} as the time needed by the i-th established metastasis to grow to the detectable
size M , counting again from its initiation. Since the processes Si(s) are independent, the hitting times Θi
are also independent and identically distributed. As shown in Material and Methods, for M large their
distribution asymptotically satisfies
P(Θi ≤ t | Ω
(i)
∞ ) ∼ G(t) ≡ e
−(1−q)Me−λt (2)
where Ω
(i)
∞ denotes the eventual survival for the i-th metastasis. Interestingly, the distribution G(t) is of a
Gumbel type, which generally describes the maximum of independent random variables with exponential
(right) tail. This Gumbel type has two parameters, a and b > 0, and distribution function exp(−e−
x−a
b ).
Hence, conditioned on survival, we asymptotically have Θi ∼ Gumbmax
(
logM(1−q)
λ ,
1
λ
)
for every i.
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Figure 2: Relapse time densities fτ (t) =
d
dt
P(τ ≤ t) computed from equation 4 for logistic and exponential primary
growths and ν = 10−10, 10−11, 10−12, 10−13, 10−14 cells/day from left to right. Using parameter estimates for col-
orectal cancer (see Table 2), the logistic densities (dashed lines) converge to the corresponding exponential ones as
the initiation rate increases. Furthermore, in the exponential case and for all the above values of ν, the densities
derived from equation 4 and their approximation obtained from equation 6 are indistinguishable.
2.2 Time to reach detectable size
Given the definitions in the previous section, we have that the i-th metastasis reaches detectable size at
time τi := σi + Θi, measured from primary onset. Metastases are initiated at time s at rate ν(1 − q)n(s)
and then reach the detectable size before t with probability G(t−s) for s ≤ t. Hence, the thinning property
of Poisson processes yields that metastases which become detectable by time t are initiated at time s at
rate ν(1−q)n(s)G(t−s). Consequently, the number of metastases detectable by t follows a Poisson process
(Ss)0≤s≤t with respect to time s for a fixed t. In particular, the number St of such metastases established
by t is thus a Poisson random variable with mean
bt = E[St] = ν(1 − q)
∫ t
0
n(s)G(t− s)ds (3)
The relapse time is defined as the first time that any metastasis reaches the detectable size, τ := mini{τi}.
Hence, τ is smaller than t if by that time at least one metastasis that becomes detectable before t is initiated,
and so
P(τ ≤ t) = P(St ≥ 1) = 1− e
−bt (4)
A sample realisation of our model, including the relapse time τ , is depicted in Figure 1. In the large
detectable sizeM limit, the relapse time distribution converges to a simpler form (see Material and Methods)
τ −
1
λ
logM
d
−→ τ
where the random variable τ¯ is distributed as
P(τ¯ ≤ t) = 1− exp
(
−ν(1− q)
∫ t
−∞
n(t− s)e−(1−q)e
−λs
ds
)
(5)
Hence for largeM the relapse time decomposes as τ ≈ 1λ logM + τ into a deterministic part which depends
only on λ and M , plus random fluctuations described by τ¯ . This decomposition leads to the estimate
E[τ ] ∼ 1λ logM+C for the expected value of the relapse time, where the constant C = E[τ¯ ] can be obtained
from equation 5.
2.3 Exponential population growth
Two commonly employed primary growth functions are the exponential and the logistic ones (see e.g. [33]).
These are given by n(t) = eδt and n(t) = Ke
δt
K+eδt−1 , respectively, where δ denotes the primary tumor net
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Figure 3: Relapse time distribution for an exponentially growing primary tumor using parameter estimates for
colorectal cancer (see Table 2). Symbols represent simulation results for a deterministic (diamonds) or a stochastic
primary growth (circles, see discussion at the end of the parameter estimation section), while solid lines correspond
to the theory in the small ν - large M limit. On the left, each starred dot denotes the mean of 1000 simulations, while
lines represent the theoretical expectation given by equation 7. These match the simulated means well for values of
ν = 10−6 or less. On the right, the relapse time densities derived from equation 14 yield a good approximation of the
simulated data (10000 simulations per curve) for M = 100 or greater for both deterministic and stochastic primary
growth.
growth rate and K a carrying capacity. Relapse time densities for these two growth types and different
initiation rates are shown in Figure 2. We observe that as ν increases, the logistic distributions converge to
the exponential ones (see Material and Methods for more details). Moreover, for all our parameter estimates
our model predicts the same results with these two growth types. The reason is that the metastases
determining the time to relapse are initiated during the early phase of tumor evolution which is almost
exponential even for a logistic growth. Therefore, from now on we will focus on exponentially growing
primary tumors. Exponential growth has the additional advantage that if only a portion of primary cells
can metastasize and their number is proportional to n(t)γ (say only cells close to the surface of a spherical
tumor for γ = 2/3), then this would be equivalent to changing the primary net growth rate, that is using
n(t) = eγδt.
Since the initiation rate ν is by far the slowest rate in our model, here we study in detail the most
relevant case, that is the small ν limit for an exponentially growing tumor. The deterministic part of the
relapse time remains 1λ logM , but interestingly the fluctuations τ¯ are distributed as
τ¯ ∼ Gumbmin
(
−
1
δ
log
ν(1 − q)1−
δ
λΓ
(
δ
λ
)
λ
,−
1
δ
)
(6)
This Gumbel distribution describes the minimum of independent random variables with exponential (left)
tail, has two parameters a and b < 0 and distribution 1 − exp(−e−
x−a
b ). Parameter a describes a shift in
the distribution, and since a ∼ log ν, it explains the equal spacing between the densities in Figure 2 for
logarithmically-spaced values of the initiation rate. Also notice that these curves are left skewed, as it is
expected from the Gumbel for the minimum. On the other hand, the Gumbel for the maximum - which
describes the fluctuations of the time to detection starting from a single initial cell - is right skewed. For
small initiation rates ν and large detectable sizes M , the mean relapse time is approximately given by
E[τ ] ≈
1
λ
logM +
1
δ
log
δ
ν
+ C , C = −
1
δ
(
log
δ(1− q)1−
δ
λΓ
(
δ
λ
)
λ
+ γE
)
(7)
where γE ≈ 0.5772 denotes the Euler-Mascheroni constant. As shown by Figure 3, this expression fits
simulations even for relatively large values of ν and small values of M .
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Equation 7 highlights a simple dependence of the mean relapse time E[τ ] on M and ν. In Material and
Methods we also compute the mean time to detectability of the first established metastasis, E[τ1], where
τ1 = σ1 + Θ1 is equal to the sum of the first initiation time and the hitting time to M . Interestingly E[τ1]
has the same M and ν dependence shown in equation 7, but the constant term C˜ is different. For example,
using the parameter estimates for colorectal cancer (see Table 2) we find C ≈ 250 and C˜ ≈ 309. The reason
for this difference is that even in the small ν - large M limit, later established metastases can outrun the
earlier ones in reaching M first.
While the mean relapse time τ shows logarithmic increase in terms of M and δ/ν, its variance stays
constant, Var(τ) = pi2/(6δ2), see equation 15. Hence, due to the slow logarithmic growth of the mean, the
fluctuations of the relapse time stay relevant even for large detection sizes and small mutation rates.
2.4 Relapse time with resection
Surgery is still the most common and effective type of treatment for solid tumors, although often used
in combination with other kind of therapies (see e.g. [34]). However, how the time of resection affects
prognosis, and in particular the estimation of the time to relapse, is still unclear. In order to investigate
this question in a theoretical framework, we now embed surgery in our model and study how it changes the
distribution of the time τ to relapse. Let us assume that at a given moment after detection a primary solid
tumor is surgically removed. This event can be mathematically implemented in our model by considering
a resection time T such that n(t) ≡ 0 for t ≥ T . In particular, this implies that after T no metastases
can be initiated. The number of metastases already established at resection is equal to KT , and their size
distribution is given in [16]. The distribution of the time τ to relapse can then be expressed exactly as
in equation 4, however here τ is not a proper random variable. In fact, as
∫∞
0
n(s)ds =
∫ T
0
n(s)ds < ∞,
there is a positive probability that no metastasis will ever occur (notice that from this point of view our
framework can be seen as a cure model - see e.g. [35]) and in this case we set τ = ∞. The distribution of
the relapse time conditioned on at least one metastasis being established by resection is simply
P(τ ≤ t | KT ≥ 1) =
P(τ ≤ t)
P(KT ≥ 1)
=
1− e−bt
1− e−aT
(8)
where we used that a relapsing metastasis had to be initiated before resection, that is {τ ≤ t} ⊂ {KT ≥ 1}.
This conditional distribution for different resection times is depicted in Figure 4. In this and following
figures, the resection time is shown at the bottom of the figure, and the corresponding resection size
N = eδT is shown on the top. As T → 0 all metastases have to be initiated close to time zero, so the
relapse time becomes the time to reach size M from a single cell, which has the Gumbel distribution for
the maximum given by equation 2. If we then increase the resection time, the conditional densities shift
to the right by the same amount. Finally, as T → ∞ the relapse time distribution converges to the case
without resection
P(τ ≤ t | KT ≥ 1)→ P(τ ≤ t)
The fluctuations for the unconditional distribution follow a Gumbel type for the minimum, as per equation 6.
Hence, as time increases, the relapse time distribution turns from a right-skewed Gumbel to a left-skewed
Gumbel.
Note that the densities in Figure 4 become indistinguishable from the large time limit as P(KT ≥ 1)
approaches one. The reason is that by this time metastases have probably already been initiated and one
of the early established ones is likely to relapse first. This suggests that only early enough resection times
change the behaviour of the model. For example in the case of colorectal cancer, according to Figure 4,
only resections of tumors smaller than 109 cells affect the time to recurrence.
Right skewed densities are often chosen to fit probability distributions arising in survival analysis. This
is due to the fact that most survival data suffer from right censoring [36], where only a lower bound is
known for data points. Looking at the densities in Figure 4, though, we can see both left and right skewed
distributions. While a few survival datasets are negatively skewed [37], cancer relapse times are typically
right censored as a consequence of limited follow-up and patients decease before relapse (see e.g. [38]).
However, our model does not take into account any of these events. Furthermore [39] recently proposed
a model for the estimation of screening times for colorectal cancer based on the observation that some
datasets suffer from left censoring as well.
2.5 Metastasis classification
If the resection is successful and the primary tumor is completely removed, the therapy can still fail due
to the formation of metastases. For this reason, it is common practice to start looking for detectable
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Figure 4: Relapse time densities fτ (t | KT ≥ 1) conditioned on at least one metastasis initiated by the time of
resection T . For different values of T , marked with ticks of corresponding colors, these densities are computed by
differentiating equation 8. As T becomes larger, the probability of metastases being established before resection (see
equation 1) increases and the conditional relapse time densities converge to the red limit one. Here we have used
parameter estimates for colorectal cancer (see Table 2), n(t) = eδt and 7 equally spaced resection times between 0.25y
and 16.15y. The curves for T > 15y look identical to the limit density.
metastases several weeks before the surgery. In this section we thus want to characterize the metastases
which are detectable at a given time and those which are not.
In general, for a fixed time t, the metastasizing process (Ks)0≤s≤t can be split into two independent
Poisson processes (Ss)0≤s≤t and (Ms)0≤s≤t describing the initiation of metastases which reach size M
before or after t, respectively. Following the same argument we used to derive the relapse time distribution,
we obtain that
St ∼ Pois (bt) , Mt ∼ Pois (ct)
where
ct = at − bt
In particular, we have that the events {τ > t} and {St = 0} are equivalent. We also stress that the
definitions above naturally extend to the case of a primary resection, by simply redefining n(t) to be zero
after the resection time T .
Now, despite an ongoing discussion on the following nomenclature (see e.g. [40]), in the rest of the
paper we will call a metastasis synchronous if it reaches the detectable size M before or up to the time of
resection, and metachronous otherwise (hereby the choice of notation St and Mt). These characterizations
immediately allow us to estimate the probability of some clinically relevant events. The probability of no
synchronous metastases is equal to
P(ST = 0) = P(τ > T ) = e
−bT (9)
Also, under this condition, relapse is not certain: the probability that at least one metastasis was initiated
given that there are no visible ones at resection is
P (KT ≥ 1 | ST = 0) = P(MT ≥ 1) = 1− e
−cT (10)
since ST andMT are independent. In next section we will study the above and related quantities in greater
detail.
3 Discussion
In this section we compare the predictions provided by our model with clinical data collected for different
cancer types. To this purpose, we first need to estimate the parameter values for each of these cancer types.
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3.1 Parameter estimation
The net growth rates of the primary and metastatic tumors, δ and λ, are inferred from the corresponding
tumor volume doubling times (denoted DTpt and DTm, respectively) as
δ = log 2/DTpt , λ = log 2/DTm
These times have been studied by many authors, starting from the influential papers of [32, 41, 42]. Many
authors still refer to these early works, although in some case more recent estimates are available. Colorectal,
breast and lung cancers are the most frequently studied. Furthermore, more papers focus on primary
doubling times than on metastatic ones.
Similarly, the birth rate α is derived from the potential doubling time Tpot, defined as the average time
between cell divisions in the absence of cell death [43, 44, 45]. In this case we simply use the estimation
α = 1/Tpot
Note that some authors (see e.g. [46]) define instead Tpot as the tumor doubling time in absence of cell
death. While in this paper we employ the former definition, the latter would simply yield a factor log 2 in
the formula above.
As for the primary tumor size N at resection, many studies report data on the primary maximum
diameter, allowing for ellipsoidal forms. However, given the relatively small tumor volume and the wide
interpatient variability, we assume a spherical shape and estimate dpt from the corresponding typical range.
By also assuming 109 cells per cm3, the primary size at resection (expressed in number of cells) is thus
estimated as N = 16pid
3
pt10
9.
Table 1 summarizes typical ranges of these quantities for five different cancer types, together with the
estimates we picked for our model and the corresponding literature references. Difficulties in distinguishing
between primary and secondary tumors or in tracking down the primary origin of a metastatic cancer
could in principle affect some of these data, but the wide range and multiple references reported reduce the
potential impact of this effect.
Table 1: Typical ranges of volume doubling times for the primary tumor (DTpt) and metastasis (DTm), tumor
potential doubling time (Tpot) and tumor diameter at resection (dpt) for breast, colorectal, headneck, lung and
prostate cancer.
Cancer type Parameter Typical range Estimate References
Breast
DTpt (days) 103− 353 210 [47, 48, 49, 50, 51, 52]
DTm (days) 85− 199 105 [53, 54]
Tpot (days) 8− 35 15 [44, 55]
dpt (cm) 1.4− 3 2.5cm [56, 57, 58]
Colorectal
DTpt (days) 130− 438 175 [59, 60, 61]
DTm (days) 45− 155 105 [62, 54, 63, 64]
Tpot (days) 3− 4 4 [65, 55]
dpt (cm) 3.5− 5.1 4.5cm [59, 66, 61, 67]
Headneck
DTpt (days) 15− 256 84 [68, 69]
DTm (days) 9.5− 320 56 [70, 71]
Tpot (days) 1− 14 4 [65, 72]
dpt (cm) 1.3− 4 2.8cm [73, 74]
Lung
DTpt (days) 22− 269 168 [75, 76, 54, 77, 78]
DTm (days) 32− 98 56 [42, 79]
Tpot (days) 2− 17.5 2.5 [75, 80]
dpt (cm) 1.7− 4.1 2cm [81, 82, 77]
Prostate
DTpt (days) 36− 1080 392 [83, 84, 85]
DTm (days) 29− 213 98 [86, 85]
Tpot (days) 15.2− 97.8 34 [87, 84]
dpt (cm) 0.1− 2.9 1.2cm [88, 89]
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Notice that by estimating the rates λ and α we also infer values for the death rate β = α − λ and the
extinction probability q = 1−λ/α. For the two remaining parameters, namely the initiation rate ν and the
minimal detectable size of a metastasisM , we use common estimates across different cancer types. Various
studies report a lowest detectable tumor diameter of 0.2cm for different cancer types (see e.g. [90, 91, 92]),
corresponding to M ≈ 4.19× 106 cells. Moreover, several papers argue that the first metastases are likely
to be established long before the detection of the primary tumor (see for example [54] and the references
therein). In particular, the review of the progression model for metastases formation in [24] reports that
dissemination starts when the primary diameter is between 0.1 and 0.4cm. We thus consider the primary
tumor size at the expected time of the first metastasis initiation and estimate it to be eδE[σ1] = 108 cells,
corresponding to a diameter of about 0.58cm. Hence, by using the results in Material and Methods, we set
ν =
δe−γE
1− q
e−δE[σ1]
Finally, the carrying capacity for the logistic primary growth studied in Figure 2 is set to K = 1012 [24, 93].
Overall, we thus found estimates for the following input vector
(DTpt, DTm, Tpot, dpt, dm, e
δE[σ1])
and used them as described above to derive values for our model parameters, i.e.
(δ, λ, ν, q,N,M)
Such estimates are summarized in Table 2.
Before we proceed to study our model predictions, let us further discuss the assumption of a deterministic
primary tumor growth function. Firstly, as we just showed, the only data we found to infer the rate of
growth of a primary tumor refer to doubling times, whose notion implicitly assumes an exponential growth.
For this reason we focus here on growth functions that (at least in their early stages) show an exponential
behaviour. Other growth functions, for example n(t) = ct3 for spherically growing tumours or n(t) = c′t2
for tumors with active cells only around the surface, could be studied when more data becomes available.
Secondly, one could model not just the metastases but also the primary tumor growth as a branching
process to account for further stochastic effects. However, due to the large tumor size at resection a
branching process model would predict an almost perfect exponential growth around resection time. For
this reason we set n(t) = eδt, which then determines the initial time t = 0. Note that the tumor is not
initiated precisely at t = 0, but that time is distributed according to a Gumbel distribution, analogously
to the results in the Single type process section in Materials and methods. Since the initiation time is not
accessible experimentally anyway, for simplicity we use this above definition for t = 0. In order to justify the
exponential deterministic approximation for the primary size, we performed simulations where we modelled
the primary tumor as a branching process as well. We found that for initiation rates of ν = 10−5 or less
(and all other parameters set for colorectal cancer) the exponential approximation of the primary causes
less than a few percent error in the relapse time distribution (see Figure 3). The relationship between
stochastic and deterministic wild type populations has been studied rigorously in [29].
Table 2: Parameter estimates for the primary net growth rate δ, the metastatic net growth rate λ, the initiation rate
ν, the extinction probability q, the primary tumor size at resection N and the minimal detectable size M .
Breast Colorectal Headneck Lung Prostate
δ (cells/day) 0.0033 0.0040 0.0083 0.0041 0.0018
λ (cells/day) 0.0066 0.0066 0.0124 0.0124 0.0071
ν (cells/day) 1.87× 10−10 8.42× 10−10 9.36× 10−10 7.49× 10−10 4.13× 10−11
q 0.9010 0.9736 0.9505 0.9691 0.7595
N (cells) 8.18× 109 4.77× 1010 1.15× 1010 4.19× 109 9.05× 108
M (cells) 4.19× 106 4.19× 106 4.19× 106 4.19× 106 4.19× 106
3.2 Model predictions
Now that we have estimated the parameters of our model in Table 2, we are in position to study its
predictions and compare them to clinical data.
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Figure 5: Probability of extant metastases, P(KT ≥ 1), dashed curve computed from equation 1, and synchronous
metastases, P(ST ≥ 1), solid curve computed from equation 4. These probabilities are plotted as functions of the
resection time T for five different cancer types. The primary tumor size at resection is N = eδT and thus depends
on the primary net growth rate. These resection sizes are discussed in Table 3. For each cancer type, the shaded
areas highlight resection time intervals leading to a probability higher than 85% of established and all undetectable
metastases. Using the parameter estimates from Table 2, the widths of these intervals are 3.41, 3.17, 1.92, 0.94, 1.19
years for breast, colorectal, headneck, lung and prostate cancer respectively.
Let us start by analyzing the simplest predictions of the model, which are about the presence of
synchronous and metachronous metastases. Figure 5 shows the probability of initiated metastasis by
resection P(KT ≥ 1) = 1 − e
−aT (equation 1), and the probability of visible metastasis by resection
P(ST ≥ 1) = 1 − e
−bT (equation 4) as functions of the resection time T , for five different cancer types.
From the figure we notice that, obviously, the probability of having initiated metastasis is always higher
than the probability of having visible metastasis at resection. For all five cancer types considered, one or
more metastases have likely been initiated by the time the primary tumor reaches about 8.2 × 108 cells
(diameter 1.16cm). While this value is similar across different primary types (as a consequence of the
parameters estimation procedure), the results for the probability of synchronous metastases vary widely.
For breast, colorectal, headneck, lung and prostate cancer, Table 3 reports primary tumor sizes at which
synchronous metastases might start to appear and are likely to be present, respectively (expressed both
in terms of number of cells and tumor diameter). By comparing these values to typical resection sizes in
Table 1, we find that detecting metastases at resection is very likely for lung and prostate cancer and rare
for headneck primary tumors.
Table 3: Resection sizes of the primary tumor which yield a 1% and 99% probability of synchronous metastases,
respectively. For each cancer type considered, these sizes are computed with the parameter values in Table 2 and
expressed both in terms of number of cells, N , and tumor diameter, d.
Breast Colorectal Headneck Lung Prostate
P(ST ≥ 1) > 0.01
N 1.32× 109 2.13× 109 7.03× 109 1.03× 108 6.27× 107
d 1.36 1.60 2.38 0.58 0.49
P(ST ≥ 1) > 0.99
N 6.03× 1011 9.88× 1011 3.22× 1012 4.65× 1010 2.89× 1010
d 10.48 12.36 18.32 4.46 3.81
One of the most challenging scenarios for the development of an effective treatment is when there are
only undetectable metastases present. In our framework this scenario corresponds to the event
UT := {KT ≥ 1, ST = 0} (11)
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Figure 6: Probability of established and all metachronous metastases - P (UT ), as given by equation 12 - plotted as a
function of T and δ (left panel) and of T and ν (right panel). The parameter estimates used are those for colorectal
cancer reported in Table 2. The plots show that the width of the high-risk interval - the range of resection times such
that P(UT ) is high - stays roughly constant for most parameter values. This width (about 3 years) shrinks only for
metastases growing significantly faster than the primary tumor that initiated them.
which has probability (see equations 9 and 10)
P(UT ) = P(MT ≥ 1, ST = 0) = P(MT ≥ 1)P(ST = 0)
= e−bT − e−aT = P(KT ≥ 1)− P(ST ≥ 1)
(12)
Because of the last identity, the probability of established and all metachronous metastases can be read out
from Figure 5 as the difference of the two curves. There, the shaded areas highlight intervals of resection
times yielding P(UT ) > 85%. These intervals, often referred to as high-risk period [94], are especially wide
for breast, colorectal and headneck cancers. The reason is that these cancer types have a lower ratio of
metastatic over primary net growth rates, so metastases take longer to grow to visible size. Hence, although
for these cancer types metastases grow slower, which improves prognosis, they stay undetectable for longer,
which poses a challenge for diagnosis. The estimated resection sizes given in Table 1 fall within or close to
these ranges ( P(UT ) equal to 93.87%, 79.83%, 98.35%, 66.04% and 85.85% for the five primary tumor types
studied, respectively). In general, by assuming that the primary tumor diameter at resection fits a normal
distribution (with mean computed as the mean of dpt and variance set so that 95% of the observations
belong to its typical range, see Table 1) we estimate that resections for breast and headneck cancers fall in
the high-risk window 99.8% and 99.58% of the times respectively, followed by colorectal (24.67%), prostate
(13.41%) and lung (0.69%) cancers.
In order to check how robust the presence of a wide high-risk interval is, we plotted in Figure 6 the
probability of having only undetectable metastasis at detection, P (UT ), for different values of the primary
net growth rate δ and of the initiation rate ν. Other parameters are taken for colorectal cancer. The width
of the high-risk interval is constant with respect to ν, and shrinks only as the ratio between the primary
and metastatic net growth rate becomes very small. The same qualitative behaviour can be obtained with
the parameter estimates for the other cancer types. As most metastases grow up to two times faster than
the primary tumor they originated from [24], our model suggests that for a wide choice of parameters there
is a substantial range of resection sizes that lead to a high probability of established and all undetectable
metastases.
Next, we ask how such a probability, P(UT ), influences the time to cancer recurrence. The conditional
distribution of the relapse time τ becomes
P(τ ≤ t | UT ) =
P(T < τ ≤ t | KT ≥ 1)
P(T < τ | KT ≥ 1)
=
e−bT − e−bt
e−bT − e−aT
for t ≥ T , where we used the definition of UT (see equation 11) and equation 8. From this distribution we
compute the expected relapse time measured from resection and conditioned on UT , E[τ − T | UT ]. This
11
Figure 7: Expected relapse time measured from resection, conditioned on extant but all undetectable metastases (blue
curve). The dashed line and the light blue shaded area show P(UT ) and how spread is the conditional relapse time
distribution, respectively. The parameter estimates used are those for colorectal cancer reported in Table 2. For
resection times close to zero this conditional expectation coincides with that of the Gumbel distribution given by
equation 14, at about 5 years. As T starts to increase E[τ −T | UT ] reflects the convergence highlighted for Figure 4,
first slightly decreasing and then staying constant around 4.4 years. Finally, when the resection time falls into the
high-risk window, the expected relapse time drops to zero. This suggests that the bigger the primary tumor size is at
resection, the faster relapse will occur.
expectation and the probability P(UT ) are plotted in Figure 7. We see that for resection sizes smaller
than 108 cells the relapse occurs on average between 4 and 5 years after resection, independently of the
primary size. For resection sizes around 108 cells, undetectable metastases become likely to be present and
E[τ − T | UT ] starts to decrease with tumor size. At about 19 years the probability of only undetectable
metastases present and the conditional mean relapse time both approach zero.
Let us stress that while some clinical studies report data on the whole distribution of recurrence times,
these are usually measured from a varying time of surgery, which corresponds to different primary tumor
resection sizes. Therefore, unless the distribution of relapse times is reported together with the correspond-
ing resection sizes, we cannot compare it directly to the predictions of our model. However, we expect the
variability of primary sizes at resection to average out across large cohorts of patients, which is why we
analyzed the expected value of the time to recurrence.
Using the values from Table 2 we tested our model by computing the probability of synchronous metas-
tases and the mean relapse time conditioned on established but all undetectable metastases. The predictions
from our model, typical ranges and references for each cancer type considered are summarized in Table 4.
Notice that our predictions for the mean relapse time fall on the lower end of the respective typical ranges.
This is expected since we compute the time to recurrence τ based on the minimal detectable size M , while
in practice metastases are often detected only at larger sizes.
In general, for different cancer types it is observed that metastases can grow up to 2 times faster than
the primary tumor they originated from [24], although values as high as 4 has been proposed [95]. Our
estimates fall within this range (δ/λ = 4 for prostate cancer, 3 for lung and between 1.5 and 2 for the
others).
As per the time interval from primary onset to surgery, the typical range is 15 − 25 years [43]. The
high variability in our estimates of DTpt make T fall outside that range for headneck (T = 7.69y), lung
(T = 14.71y) and prostate (T = 32y) cancers, classifying the first two as fast growing tumors and the latter
as a slow growing one. The singular features that the model predicts for prostate cancer are in accordance
with clinical studies (see e.g. [96, 86]).
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Figure 8: Disease-free curves for different resection times. The earlier the primary tumor is resected the higher
is the probability that no metastases will arise, or cure probability, represented by the value of the final plateaus.
The resection times are chosen so that P(KT = 0) = 0.75, 0.6, 0.45, 0.3, 0.15, 0.001 respectively. With the parameter
estimates for colorectal cancer (see Table 2) these times range from 12.28 to 14.48 years, corresponding to sizes
between 5.12 × 107 and 1.23× 109 cells (diameter 0.46 − 1.33cm), respectively.
Table 4: Typical ranges of P(ST ≥ 1) and E[τ − T | UT ], predicted value from the model and literature references
for each cancer type.
Cancer
type
Output Range from
clinical data
Theoretical
prediction
Reference
Breast
P (ST ≥ 1) (%) 5− 10 6.13 [97, 98, 99]
E[τ−T | UT ] (days) 590− 1022 725 [100, 101, 102]
Colorectal
P (ST ≥ 1) (%) 15− 25 20.17 [103, 104, 105, 106,
107, 99]
E[τ−T | UT ] (days) 353− 760 356 [108, 109, 106, 110,
107]
Headneck
P (ST ≥ 1) (%) 1− 16.8 1.65 [111, 112]
E[τ−T | UT ] (days) 219− 623 435 [113, 114, 115]
Lung
P (ST ≥ 1) (%) 30− 55.39 33.96 [99, 116]
E[τ−T | UT ] (days) 210− 602 249 [117, 118, 119]
Prostate
P (ST ≥ 1) (%) 10− 34 13.53 [120, 121, 122]
E[τ−T | UT ] (days) 730− 1131 969 [123, 124]
The last trait of cancer recurrence that we are going to examine is disease-free rates. These generally
correspond to the survival function of the relapse time, P(τ > t). However, following the previous discussion
we will condition this probability on no synchronous metastases, obtaining
P(τ ≤ t | ST = 0) = 1− e
−(bt−bT ) (13)
for t ≥ T . In this case we do not observe any convergence to the density without resection, because if T → 0
then no metastasis can be initiated and if T →∞ the condition ST = 0 pushes the relapse time to infinity.
Let us also stress that our model does not provide information on survival rates, as no modelling of the time
to decease is incorporated. Furthermore, notice that P (τ > t) yields a good description of the disease-free
rates in terms of metastases detectability, but not necessarily with respect to cancer symptomaticity.
The relapse time distribution in case of no synchronous metastasis, P(τ > t | τ > T ), for different
resection times is shown in Figure 8, studying again the case of colorectal cancer. As we are not conditioning
13
Figure 9: Probability of the first metastasis being initiated during surgery delay. This probability P(KT+∆T ≥
1, KT = 0) - where T is the set time of resection and ∆T the surgery delay - is plotted as a function of the resection
size N = eδT (x-axis) and of the delay ∆T (y-axis). With the parameter estimates for colorectal cancer (see Table 2)
we see that if a primary tumor is resected at a critical size (around 2 × 108 cells, diameter ≈ 0.725cm), surgery
delays of 2-3 months can decrease the cure probability of more than 10%.
on at least one metastasis being initiated, there is always a positive probability that relapse will not occur,
that is τ =∞. The resection times are thus chosen so to yield cure probabilities - P(KT = 0), corresponding
to the final plateaus - equal to 0.75, 0.6, 0.45, 0.3, 0.15 and 0.001, respectively. These times span across a
total range of about 2.2 years. Furthermore, excluding the latest resection time considered, the difference
between two consecutive of these T values is between 0.28 and 0.4 years. Hence, our model suggests that
delays of the order of months in the time of primary resection can lead to a significant decrease in the cure
probability.
To quantify more precisely the implications of surgery delays, we study the probability that the first
metastasis is initiated in the time interval (T, T +∆T )
P(KT+∆T ≥ 1,KT = 0) = P(KT+∆T ≥ 1)− P(KT ≥ 1).
This probability is depicted in Figure 9 using our parameter estimates for colorectal cancer. We see in the
figure that there is a middle range of resection sizes where the recurrence probability can be significantly
affected by small surgery delays. For colorectal cancer we estimate that if the primary resection is origi-
nally planned for a tumor of diameter between 0.44 and 0.9 centimeters (4.39 × 107 and 3.89 × 108 cells,
respectively), then a surgery delay of 60 days would decrease the cure probability by 5 − 9%. Conversely,
tumors smaller than this critical range are less likely to metastasize during the surgery delay, while larger
tumors likely metastasized already, so that the effect of surgery delay for these sizes is smaller.
3.3 Conclusions
We introduced a model of metastasis formation where metastases are initiated at a time dependent rate, in
the simplest case proportional to the size of a growing primary tumor. All initiated metastases then evolve
as independent supercritical branching processes. Parameters of the model were estimated for five different
cancer types from the clinical literature. We studied the relapse time τ , that is the earliest time when any of
the metastases becomes detectable. We obtained the distribution of τ for a general primary tumor growth
and focused in particular on logistic and exponential growth functions. For clinically relevant initiation
rates the metastases which relapse first are typically initiated in the early phase of the primary tumor
development, which is exponential for both growth functions considered. Hence the distributions of τ for
exponential and logistic primary growths are practically identical unless the initiation rate is unrealistically
small (ν ≈ 10−13 or smaller) and we can thus exploit the much simpler formulas for the exponentially
growing tumor.
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We model the resection of the primary tumor by introducing a cut-off for the growth function n(t). If
metastases are likely already established at surgery, their time of relapse is not influenced by the resection
timing. We categorized all metastases into synchronous and metachronous and computed corresponding
occurrence probabilities. With our estimated parameters we found that the probability of synchronous
metastases and the mean relapse time after resection falls in the typical clinical range for all five different
cancer types we study.
A challenging scenario for treatment is that of patients with established but all undetectable metastases.
For all five cancer types we considered, the probability of this event is high within a significant range of
resection sizes. Unfortunately, the typical size of a resected tumor falls in or near this range for all cancer
types. We found that relatively small delays in these resection times can cause significant decrease in the
cure probability. Within our model, surgery only prevents recurrence if it is done before the onset of the
first surviving metastases.
The parameter estimates summarized in Table 2 yield realistic predictions for several quantities of
clinical interest. Although in principle we can explore our model predictions across the whole range of
parameters, this would often lead to unrealistic outcomes. In this sense the quantitative predictions of
our model are quite sensitive to the parameter values, but we have been able to find a combination of
parameters that yields realistic results. On the other hand, the qualitative features of our model are more
robust to parameter changes, as demonstrated for example in Figure 6.
In particular, our estimate for the initiation rate of metastases, ν, is based on the assumption of
early dissemination at primary size, eδE[σ1] = 108 cells. However, since the metastatic net growth rate δ
and extinction probability q are estimated independently from data on tumor volume doubling times (see
Table 1), by changing the early dissemination assumption our model predictions could fall outside their
typical ranges. For example, for colorectal cancer, assuming eδE[σ1] = 109 cells would lead to the unrealistic
values E[τ − T | UT ] = 836 days and P (ST ≥ 1) = 2.23%. Thus, indirectly, our model supports the
hypothesis of early metastatic dissemination.
Note that in this paper we focused on the presence or absence of synchronous or metachronous metastasis
at resection as these events determine if there is ever a relapse (KT ≥ 1) or if relapse has already occurred by
resection (ST ≥ 1). Our model also provides estimates for the number and sizes of metastases at resection,
but these are less relevant for the study of the time to cancer relapse, and have already been studied in
detail in [16, 29]. A general feature the model predicts is that the cumulative distribution of metastases
sizes at resection has a power law tail with exponent δ/λ. This power law tail was observed in [16] using
data on 21 patients with colorectal cancer from [13], and the exponent was found to typically be in the
range 0.3−0.8. Our estimate δ/λ = 0.61 falls in this range, supporting our parameter inference. The paper
above also reports data on the number of visible metastases at surgery. In our model, for a given primary
resection size eδT , this number is a Poisson random variable ST . However, since the primary tumor sizes
are not published and likely different for all patients in the data, we could not use this quantity reliably
for our parameter estimation. For example, if we infer the initiation rate ν for colorectal cancer from the
probability of visible metastasis at resection (given by P (ST ≥ 1) = 1 − e
−bT and with estimate 0.2 from
the data reported in Table 4) we would get essentially the same estimate as in Table 2. But by using instead
the mean number of visible metastases (expressed as E(ST |ST ≥ 1) = bT /(1− e
−bT ), with estimated lower
bound 1.4 from [107]), we would infer a 3 times greater estimate for ν. Again, a possible cause of this
discrepancy lies in the different resection sizes for patients which we have no data for.
Metastases are seeded and establish colonies via a specific and complex process called metastatic cascade
(for details see e.g. [125]). Since this is known to be a multi-stage process, some authors (see for example
[126, 6, 127] and references therein) have described metastases initiation through two-type stochastic models,
where a cell needs to gain the ability to metastasize before it can establish a new metastatic lesion. We did
not choose that route for several reasons: (i) the precise details of how and when cells reach this ability are
not clear [43, 128], (ii) in our model we can think of n(t) as the number of cells which can metastasize and
so tailor the two approaches, and (iii) if we assume that an acquired metastatic ability lowers the primary
net growth rate and that the seeding rate is sufficiently small (at most 10−4 according to simulations), a
branching process model would predict the same exponential growth for the cells with this ability [29, 129],
and hence this would only change the estimate of the initiation rate in our model.
We did not include into our model a mechanism for metastasis seeding other metastasis, although this
phenomena has been observed in clinical studies [130]. The main reason for this omission was the lack of
reliable data for the estimation of the secondary seeding rate. By assuming the same primary and secondary
seeding rates, however, we would expect metastases to initiate secondary ones when they reach around 108
cells, at which size they are already detectable. Hence, by considering this scenario our predictions for the
time to cancer relapse would not change.
We aim to compare our model in the future to data where relapse times are given jointly with primary
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tumor sizes at resection. Tumor size is of course not the only relevant factor in predicting relapse times,
so the model should be extended to involve other features like a measure of malignancy, possibly as in
[131]. Many of the parameters of the model can differ between patients, and also between each metasta-
sis. Therefore, including a probability distribution for the parameters could also make our model more
realistic, provided that such distributions can be estimated from data. Other possible extensions could
include interactions among metastatic cells and among metastatic lesions, effects of the immune system,
allowing metastases to seed other metastases, and providing an estimate for the fraction of cells which can
metastasize, perhaps through modelling angiogenesis.
4 Materials and methods
In this section we provide more details about the mathematical foundations of our model.
4.1 Single type process
Let (Zt)t≥0 be a birth-death branching process, i.e. a Markov chain on non-negative integers with transition
rates
i 7→
{
i+ 1 rate iα
i− 1 rate iβ
The two positive constants α and β are called birth and death rate, respectively. In our model we employ
this process to describe the evolution of each metastasis. We assume that all metastases have the same birth
and death rate and that they are supercritical, that is they have positive net growth rate λ = α − β > 0.
Moreover, since we only want to model surviving metastasis, we condition on the eventual survival of the
process, that is on the event Ω∞ = {ω : Zt(ω) > 0 for all t ≥ 0}. The probability of such event is equal to
P(Ω∞) = 1− q, where q = β/α [31].
We define the first passage time to size M as TM := inf{t > 0 : Zt = M}. A well known property of
branching processes is that e−λtZt → W almost surely as t→∞, and conditioned on survival and a single
initial cell W ∼ Expo(λ/α) [31]. Since W and TM are connected by lim
M→∞
Me−λTM = W , an immediate
consequence is that
P(TM ≤ t | Ω∞ ∩ {Z0 = 1}) ∼ e
−(1−q)Me−λt ≡ G(t) as M →∞ (14)
Early derivations of this result already appear in [132, 133]. Interestingly, TM follows the Gumbel distri-
bution Gumbmax
(
logM(1−q)
λ ,
1
λ
)
, where
Y ∼ Gumbmax(a, b) ⇐⇒ P(Y ≤ y) = e
−e−
y−a
b , a ∈ R, b > 0
The Gumbel type is an extreme value distribution. If Mn denotes the maximum of n IID random variables
Xi, the Gumbel distribution above generally describes the limit of Mn as n → ∞, when Xi have an
exponential (right) tail. A similar definition can be given for the reverse Gumbel distribution, i.e. the limit
of minimum of IID random variables with an exponential (left) tail
Y ∼ Gumbmin(a, b) ⇐⇒ P(Y ≤ y) = 1− e
−e−
y−a
b , a ∈ R, b < 0
For both of these distributions we have
Y ∼ Gumb(a, b) =⇒ E[Y ] = a+ bγE , Var(Y ) =
pi2
6
b2 (15)
where γE ≈ 0.5772 denotes the Euler-Mascheroni constant. Hence the mean hitting time to M cells grows
logarithmically with M , while its variance remains constant
E[TM ] =
logM(1− q) + γE
λ
, Var (TM ) =
pi2
6λ2
Thus, for sizes M ≈ α/λ the standard deviation is approximately equal to the mean, but since the mean
only grows logarithmically with M , fluctuations of TM stay relevant even for much larger values of M .
16
4.2 Scaled relapse time distribution
In Results we derive the general expression for the relapse time distribution, whose full expression is obtained
by combining equations 3, 4 and 14. Here we show how to scale the detectable sizeM out of this expression,
so to split the distribution into a deterministic part and a stochastic term. Let us focus on the integral∫ t
0
n(s)G(t − s)ds =
∫ t
0
n(s)e−(1−q)Me
−λ(t−s)
ds
and apply the change of variables z := t− s− 1λ logM to find∫ t− 1
λ
logM
− 1
λ
logM
n
(
t− z −
1
λ
logM
)
e−(1−q)e
−λz
dz
By plugging this expression back into equation 4, at time t+ 1λ logM we get
P
(
τ −
1
λ
logM ≤ t
)
= 1− exp
(
−ν(1− q)
∫ t
− 1
λ
logM
n(t− z)e−(1−q)e
−λz
dz
)
Hence, as M tends to infinity we obtain
τ −
1
λ
logM
d
−−−−→
M→∞
τ¯
where
P(τ¯ ≤ t) = 1− e−ν(1−q)
∫
t
−∞
n(t−s)e−(1−q)e
−λs
ds
From the last two equations we also see that asymptotically as M →∞
E[τ ] ∼
1
λ
logM + C, C = E[τ¯ ] (16)
4.3 Explicit results for exponential primary growth
Two commonly employed growth functions for primary tumors are the exponential ne(t) = e
δt and the
logistic nl(t) =
Keδt
K+eδt−1 ones (see e.g. [33]). A logistic growth implies that the primary tumor has a carrying
capacity K. During the first stages of its development nl(t) follows the same exponential trajectory of ne(t)
and then approaches a constant as it gets closer to size K. As the carrying capacity is typically large,
this slowdown for nl(t) happens around tˆ = log(K)/δ. The differences between the results provided by
these two growths functions thus depend on the probability of metastases being initiated by time tˆ, i.e.
P(Ktˆ ≥ 1) ≈ 1− e
−
ν(1−q)K
δ . Hence, if
ν(1− q)K
δ
≫ 1 (17)
metastases are likely established in the first stages of the primary growth, i.e. when nl(t) ≈ ne(t). Otherwise,
metastases are initiated late in the primary evolution, when the two growth functions are substantially
different. This feature is visualized in Figure 2, where τ densities for a logistic growth are shown to
converge to the exponential ones as ν increases and the other parameters are fixed.
Using the parameter values from Table 2, however, we observe that the condition in equation 17 is
satisfied for all cancer types considered. In other words, our estimates for ν, q,K and δ yield no difference
between exponential and logistic growth functions. In light of this, we study in greater detail the results
obtained with ne(t).
4.3.1 Scaled relapse time
When n(t) = ne(t) = e
δt, the relapse time distribution has an expression in terms of special functions. To
show this, let us consider the distribution of the scaled relapse time τ as given by equation 5 and focus on
the integral ∫ t
−∞
n(t− s)e−(1−q)e
−λs
ds = eδt
∫ t
−∞
e−(1−q)e
−λs−δsds
This can be equivalently written as
eδt
∫ t
−∞
1
(1− q)δ/λ
[
(1− q)e−λs
]δ/λ
e−(1−q)e
−λs
ds
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The last expression then suggests the change of variable x = (1− q)e−λs, which leads to
eδt
λ(1 − q)δ/λ
∫ ∞
(1−q)e−λt
x
δ
λ
−1e−xdx =
eδt
λ(1 − q)δ/λ
Γ
(
δ
λ
, (1− q)e−λt
)
and where Γ denotes the incomplete upper gamma function Γ(a, t) =
∫∞
t
xa−1e−xdx. The scaled relapse
time distribution for n(t) = eδt is thus given by
P(τ¯ ≤ t) = 1− exp
(
−
ν(1− q)1−
δ
λ eδt
λ
Γ
(
δ
λ
, (1− q)e−λt
))
(18)
Since Γ(1, t) = e−t, for λ = δ this simplifies to
P(τ¯ ≤ t) = 1− exp
(
−
ν
λ
e−(1−q)e
−λt+λt
)
4.3.2 Small initiation limit
While the initiation rate can vary significantly across different cancer types, ν is typically orders of magni-
tude smaller then all other parameters. Hence, we now investigate τ distribution in the ν → 0 limit. Let
us first consider the result given by equation 18 for the scaled time to recurrence τ and write it as
P(τ¯ ≤ t) = 1− exp
(
−
ν(1 − q)1−
δ
λΓ
(
δ
λ
)
eδt
λ
)
exp
(
ν(1− q)1−
δ
λφ(t)eδt
λ
)
(19)
where
φ(t) =
∫ (1−q)e−λt
0
s
δ
λ
−1e−sds <
∫ (1−q)e−λt
0
s
δ
λ
−1ds =
λ
δ
(1− q)
δ
λ e−δt
Notice that the second exponential factor in equation 19 is bounded below by 1 and above by e
ν(1−q)
δ for
all t ≥ 0. Therefore, as ν → 0, the distribution of τ¯ asymptotically converges to
P(τ¯ ≤ t) ∼ 1− exp
(
−
ν(1− q)1−
δ
λΓ
(
δ
λ
)
eδt
λ
)
Equivalently, for small initiation rates the scaled relapse time τ¯ asymptotically follows a Gumbel distribution
for the minimum, τ¯ ∼ Gumbmin
(
− 1δ log
ν(1−q)1−
δ
λ Γ( δλ )
λ ,−
1
δ
)
.
4.3.3 Mean relapse time
By combining the last result with equations 15 and 16 we find that
E[τ ] ≈
1
λ
logM +
1
δ
log
δ
ν
+ C
where C = − 1δ
(
log
δ(1−q)1−
δ
λ Γ( δλ )
λ + γE
)
. Intuitively, the time to relapse is likely to be determined by one
of the first established metastases. Given the simple dependence of E[τ ] on M and ν, we now compare it
with the mean time to detectability of the first metastasis, E[τ1]. Let us first recall that τ1 = σ1 + Θ1 is
equal to the sum of the first initiation time and the hitting time to M . As ν → 0, the distribution of the
first arrival σ1, given in general by 1 − e
−at , converges to a reverse Gumbel with parameters 1δ log
δ
ν(1−q)
and − 1δ . This implies in particular that
E[σ1] =
1
δ
(
log
δ
ν(1− q)
− γE
)
=
1
δ
log
δ
ν
+ C1
where C1 = −
log(1−q)+γE
δ . Moreover, the hitting times Θi follow the Gumbel distribution G(t) - see
equation 2 - and hence
E[Θi] =
1
λ
logM − C2
18
for every i, where C2 = −
log(1−q)+γE
λ . Joining the last two results we get
E[τ1] = E[σ1 +Θ1] =
1
λ
logM +
1
δ
log
δ
ν
+ C˜ (20)
where C˜ = C1 −C2. By comparing equation 20 with the expression for E[τ ], we notice indeed the same M
and ν dependence, but the constants C and C˜ have different analytical forms.
4.3.4 Numerical computation
Finally, all the plots and computations reported in this paper have been performed on Matlab R2018b.
The lines of code below provide an efficient way (in the example for the exponential case) to calculate the
relapse time distribution given by equation 4 for a vector of times tspan.
n = @(t)(exp (delta*t));
G = @(t)(exp (-(1-q)*M*exp (-lambda *t)));
F = @(t)(1-exp (-nu*(1-q)* integral (@(s)(n(s).* G(t-s)),0,t,’ArrayValued ’,true )));
x = arrayfun (@(t)F(t),tspan );
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